InvestorsHub Logo
Followers 65
Posts 23788
Boards Moderated 0
Alias Born 11/23/2016

Re: bas2020 post# 402242

Thursday, 02/09/2023 4:42:30 AM

Thursday, February 09, 2023 4:42:30 AM

Post# of 459917

Yun Zhong

Okay. Great. So the last question, I believe that the original plan is to initiate all those studies that you talked about by year-end last year. And I understand that the focus was on the Alzheimer's disease program. But are there any specific reason for the delay? Or -- also, are you able to provide any specific in terms of timing? When do you expect to initiate those studies?

Christopher Missling

Yeah. So we were very ambitious last year when we made those plans. And the attention to detail required really to finance and work on the specific protocol because it's easy to start any trial. It's more difficult to finish a trial successfully, and that's what we're aiming for. So I think we should appreciate that initiating a trial is not difficult, it's about making the trial successful and meaningful for when it's growing.

And so when you look at each trial, there's always things to consider and you learn to improve it as you go before you really start it. And we didn't want to rush it. So that's why we want to say -- we want to do this with the right timing. But obviously, we will catch up very nicely now with all these trials, which we plan to do. And they are still on track to be executed.


Seems to be the general trend with Missling's plans. Soon is anything from several months to years.

No answer at all to the question asked, except for:

But obviously, we will catch up very nicely now with all these trials, which we plan to do. And they are still on track to be executed.


Which just means Anavex soon and a good parallel to the Secret Rare Disease indication trial that has been hanging around for a couple of years along with expectations for the PDD study peer reviewed paper with the full "Proof of Concept" data, which will likely be the fait of the P2b/3 paper too.

Lots of planning, meaning procrastination, going on and little action. I guess it takes time to come up with the most cunning schemes for manipulating the stats for plausible deniability to show success.

Absolutely Pathetic!!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News